BFM
LRMR icon

Boothbay Fund Management’s Larimar Therapeutics LRMR Stock Holding History

Boothbay Fund Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-199,600
Closed -$645K – 2190
2025
Q3 		$645K Buy
+199,600
New +$748K 0.01% 1031

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boothbay Fund Management's LRMR Position: Q2 2025 in Review

Boothbay Fund Management sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 13,731 shares — an estimated $29.5K sold.

Boothbay Fund Management first reported a position in LRMR in Q1 2021 and held it in 11 quarters. The position peaked at $781K in Q1 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Boothbay Fund Management reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 13,731 Larimar Therapeutics shares in Q2 2025, an estimated $29.5K.
  • Boothbay Fund Management first reported a position in Larimar Therapeutics in Q1 2021 and held it in 11 quarters.
  • Boothbay Fund Management's Larimar Therapeutics position peaked at $781K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.